SV

Street Verdict

Analyst Scorecard

A record of what Arun Kejriwal said publicly, with the source. Not advice.

“Advises investors to apply for the Anthem Biosciences IPO, citing the company's strong CRDMO operations, healthy net margins of 23.4%, and a PAT of ₹451 crores for FY25. A key comforting factor is the promoter founder retaining over 52% stake and not selling any shares in this entirely offer-for-sale issue.”
Anthem BiosciencesBullishCalled 14 Jul 2025
Verdict:PENDING

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Read the original articleSee Arun Kejriwal’s full track record